A multidisciplinary research team at the University of California, Irvine, has revealed that the circadian clock can be leveraged to enhance the efficacy of checkpoint inhibitor cancer therapy.
More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
